Your browser doesn't support javascript.
loading
Translating slow-binding inhibition kinetics into cellular and in vivo effects.
Walkup, Grant K; You, Zhiping; Ross, Philip L; Allen, Eleanor K H; Daryaee, Fereidoon; Hale, Michael R; O'Donnell, John; Ehmann, David E; Schuck, Virna J A; Buurman, Ed T; Choy, Allison L; Hajec, Laurel; Murphy-Benenato, Kerry; Marone, Valerie; Patey, Sara A; Grosser, Lena A; Johnstone, Michele; Walker, Stephen G; Tonge, Peter J; Fisher, Stewart L.
Afiliação
  • Walkup GK; Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA.
  • You Z; Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA.
  • Ross PL; Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA.
  • Allen EK; Institute for Chemical Biology and Drug Discovery, Department of Chemistry, Stony Brook University, Stony Brook, New York, USA.
  • Daryaee F; Institute for Chemical Biology and Drug Discovery, Department of Chemistry, Stony Brook University, Stony Brook, New York, USA.
  • Hale MR; Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA.
  • O'Donnell J; Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA.
  • Ehmann DE; Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA.
  • Schuck VJ; Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA.
  • Buurman ET; Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA.
  • Choy AL; Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA.
  • Hajec L; Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA.
  • Murphy-Benenato K; Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA.
  • Marone V; Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA.
  • Patey SA; Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA.
  • Grosser LA; Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA.
  • Johnstone M; Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA.
  • Walker SG; Department of Oral Biology and Pathology, Stony Brook University, Stony Brook, New York, USA.
  • Tonge PJ; Institute for Chemical Biology and Drug Discovery, Department of Chemistry, Stony Brook University, Stony Brook, New York, USA.
  • Fisher SL; Infection Innovative Medicines Unit, AstraZeneca Research and Development, Waltham, Massachusetts, USA.
Nat Chem Biol ; 11(6): 416-23, 2015 Jun.
Article em En | MEDLINE | ID: mdl-25894085
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Treonina / Inibidores Enzimáticos / Amidoidrolases / Ácidos Hidroxâmicos / Antibacterianos Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Treonina / Inibidores Enzimáticos / Amidoidrolases / Ácidos Hidroxâmicos / Antibacterianos Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2015 Tipo de documento: Article